Group 2B: Triple Negative Breast Cancer; Clinical Trials; Side Effects
Thursday, Dec 14
2:00 pm – 3:30 pm Eastern Time (US/New York)
Poster #PO2-12-12:
REaCT 5G: A randomized study comparing bone pain after 5 days of filgrastim or one day of pegfilgrastim for primary febrile neutropenia prophylaxis during neo-/adjuvant chemotherapy for early breast cancer.
Poster author Terry Ng, M.D. is also the scientist for this session
Poster #PO1-18-07:
Phase I trial of combination pembrolizumab and ruxolitinib in metastatic triple negative breast cancer.
Mentor: Debbie Denardi
Debbie has been screened for breast cancer every 6 months since she was 27 years old due to her family history of breast cancer. Her mother and 3 of her sisters died after a breast cancer diagnosis in the ‘70s. They were all very young (40-45 years old). This family history was reported to every doctor she visited, but no doctor or nurse advised her to get tested for hereditary cancer. Finally, in 2010 when she was 48 years old and after 4 months of a clean mammogram and ultrasound, she was diagnosed with TNBC and a BRCA1 mutation.
Since her diagnosis and lack of education about hereditary cancers, she has been learning as much as she can to educate individuals and families about hereditary cancer. She started her volunteer work with FORCE (Facing Hereditary Cancer Empowered) and has served as a peer support leader in S. Florida since 2012. She also serves as the Treasurer for FORCE’s Board. During the first few years of her advocacy, she attended conferences and continued her local support. In 2018, she had the opportunity to start a new phase of her career and education in advocacy.
Twitter: @debsetu
Scientist: Terry Ng, M.D.
Dr. Terry L. Ng, MD, FRCPC, is a medical oncologist at The Ottawa Hospital Cancer Centre, with an appointment of Assistant Professor at the University of Ottawa and Clinician Investigator at the Ottawa Hospital Research Institute.
He has published on a broad spectrum of topics focused on supportive and palliative cancer care, molecular targeted therapies, immunotherapy, and gut microbiome. In the clinic he provides care for patients diagnosed with breast cancer and brain cancer. He has a special interest in triple negative breast cancer and glioblastoma.
He has led and conducted multiple investigator initiated studies including REaCT-5G (bone pain with 5 days of filgrastim vs pegfilgrastim), REaCT HOLD BMA (continue bone modifying therapy vs. reduce to every 6 months after completing two prior years of BMA treatment), REaCT OGF (continue vs. omit G-CSF during dose-dense paclitaxel after 4 cycles of neo-/ adjuvant dose-dense AC), and THERABIOME-GBM (prospective cohort study assessing gut microbiome throughout treatment course of newly diagnosed glioblastoma).
